


**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6556-68013
Application Number	10/808,880
Filing Date	March 24, 2004
First Named Inventor	Watkins
Art Unit	
Examiner Name	

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
SS		3,847,550	11/12/1974	Scott <i>et al.</i>
SS		5,075,101	12/24/1991	Siguel
SS		5,773,300	06/30/1998	Federighi <i>et al.</i>
SS		6,185,561	02/06/2001	Balaban <i>et al.</i>
SS		6,188,783	02/13/2001	Balaban <i>et al.</i>
SS		6,223,127	04/24/2001	Berno
SS		6,229,911	05/08/2001	Balaban <i>et al.</i>
SS		6,308,170	10/23/2001	Balaban
SS		6,576,471	06/10/2003	Otvos

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
SS		WO 99/05574	04 Feb. 1999	PCT
SS		WO 99/05591	04 Feb 1999	PCT
SS		WO 99/32660	01 July 1999	PCT
SS		WO 01/04622	18 Jan. 2001	PCT
SS		WO 01/20043	22 Mar. 2001	PCT
SS		WO 01/23614	05 Apr. 2001	PCT

EXAMINER SIGNATURE:	/Sandra Saucier/	DATE CONSIDERED:	12/13/2006
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	6556-68013
		Application Number	10/808,880
		Filing Date	March 24, 2004
		First Named Inventor	Watkins
		Art Unit	
		Examiner Name	

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS	
		Boersma <i>et al.</i> , "19F NMR metabolomics for the elucidation of microbial degradation pathways of fluorophenols," <i>Ind. Microbial Biotechnol.</i> , 26(1/2):22-34, January 2001 (Abstract only) <i>Duplicate</i>	→
SS		Fiehn, "Combining genomics, metabolome analysis, and biochemical modelling to understand metabolic networks," <i>Comp. Funct. Genom.</i> , 2:155-168, 2001	→
		Griffin <i>et al.</i> , "Metabolic Profiling of Genetic Disorders: A multitissue (1)H Nuclear Magnetic Resonance Spectroscopic and Pattern Recognition Study into Dystrophic Tissue," <i>Anal. Biochem.</i> , 293(1):16-21, June 1, 2001 (Abstract only) <i>Duplicate</i>	→
		Jardine and Holdaas, "Fluvastatin in combination with cyclosporin in renal transplant recipients: A review of clinical and safety experience," <i>J. Clinical Pharmacy and Therapeutics</i> , 24(6):397-408, December 1999 (Abstract only) <i>Duplicate</i>	→
		Lithell, "Hypertension and hyperlipidemia: A review," <i>Am. J. of Hypertension</i> , 6(11):303S-308S, 1993 (Abstract only) <i>Duplicate</i>	→
SS		Raamsdonk <i>et al.</i> , "A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations," <i>Nature Biotechnology</i> , 19:45-50, January 2001	→
		Saudek and Eder, "Lipid Metabolism in Diabetes Mellitus," <i>Am. J. Med.</i> , 66(5):843-852, 1979 (Abstract only) <i>Duplicate</i>	→
SS		Siguel <i>et al.</i> , "Criteria for essential fatty acid deficiency in plasma as assessed by capillary column gasliquid chromatography," <i>Clin. Chem.</i> , 33(10):1869-1873, October 1987 (Abstract only)	→
NO DATE		Siguel, "Diagnosing Essential Fatty Acid Deficiency," <i>Circulation</i> , 97(25):2580-2583 <i>Duplicate</i>	→
		Siguel <i>et al.</i> , "Monitoring the optimal infusion of intravenous lipids. Detection of essential fatty acid deficiency," <i>Arch. Pathol. Lab. Med.</i> , 110(9):792-797, September 1986 (Abstract only) <i>Duplicate</i>	→
		Siguel and Maclure, "Relative activity of unsaturated fatty acid metabolic pathways in humans," <i>Metabolism</i> , 36(7):664-9, July 1987 (Abstract only) <i>Duplicate</i>	→
		Tanaka and Hine, "Compilation of gas chromatographic retention indices of 163 metabolically important organic acids and their use in detection of patients with organic acidurias," <i>J. Chromatogr.</i> 239:301-322, April 30, 1982 (Abstract only) <i>Duplicate</i>	→
		Tate <i>et al.</i> , "Lipid metabolite peaks in pattern recognition analysis of tumour <i>in vivo</i> MR spectra," <i>Anticancer Res.</i> , 16(3B):1575-1579, May-Jun, 1996 (Abstract only) <i>Duplicate</i>	→
		Fretheim, "Gene discovery via metabolic profiling," <i>Curr. Opin. Biotechnol.</i> , 12(2):135-138, April 2001 (Abstract only) <i>Duplicate</i>	→

EXAMINER SIGNATURE:	/Sandra Saucier/	DATE CONSIDERED:	12/13/2006
---------------------	------------------	------------------	------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	6556-68013
		Application Number	10/808,880
		Filing Date	March 24, 2004
		First Named Inventor	Watkins
		Art Unit	
		Examiner Name	
		Tweeddale <i>et al.</i> , "Effect of slow growth of metabolism of <i>Escherichia coli</i> , as revealed by global metabolite pool ("metabolome") analysis," <i>J. Bacteriol.</i> , 180(19):5109-5116, October 1998 (Abstract only)	<i>Duplicate</i>
		Vigneau-Callahan <i>et al.</i> , "Characterization of diet-dependent metabolic serotypes: analytical and biological variability issues in rats," <i>J. Nutr.</i> , 131(3):924S-932S, March 2001 (Abstract only)	<i>Duplicate</i>
		Waters <i>et al.</i> , "NMR and pattern recognition studies on liver extracts and intact livers from rats treated with alpha-naphthylisothiocyanate," <i>Biochem. Pharm.</i> , 64(1):67-77, July 1, 2002 (Abstract only)	<i>Duplicate</i>
SS		Watkins <i>et al.</i> , "Individual metabolism should guide agriculture toward foods for improved health and nutrition," <i>Am. J. Clin. Nutr.</i> , 74:283-286, 2001	
SS		"Functional Genomics in Aberystwyth," http://gepasi.dbs.aber.ac.uk/dbk/fungen.htm , (1 page) printed 06/16/2001	
SS		Hofestädt and Thelen, "Quantitative Modeling of Biochemical Networks," http://www.bioinfo.de/isp/1998/01/0006/main.html , (12 pages), printed 05/20/2002	
SS		Siguel, "A New Relationship Between Polyunsaturated Fatty Acids and Total/HDL Cholesterol," <i>Lipids</i> , 31:S51-S56, 1996, http://www.efafod.com/tchdlc.htm , (6 pages) printed 06/09/2001	
SS		Siguel, "How to evaluate a laboratory that performs fatty acid analysis," http://www.efafod.com/goodlab.htm , (8 pages) printed 06/09/2001	
SS		Siguel, "High total calories and low EFAs are more likely than fat to be the major culprit in heart disease and cancer," http://www.efafod.com/lowfat.htm , (6 pages), printed 06/09/2001	

EXAMINER SIGNATURE:	/Sandra Saucier/	DATE CONSIDERED:	12/13/2006
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			



ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for Form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/808,880
(Use as many sheets as necessary)				Filing Date	March 24, 2004
Sheet	1	of	2	First Named Inventor	Steven M. WATKINS
				Art Unit	1651
				Examiner Name	S. Saucier
				Attorney Docket Number	475512000400

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
SS	1.	WO-03/005628-A2,A3	01-16-2003	Lipomics Technologies, Inc.	
SS	2.	WO-03/028271-A2,A3	04-03-2003	Lipomics Technologies, Inc.	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
SS	3.	Aarsland, A. et al. (1998). "Hepatic Secretion of VLDL Fatty Acids During Stimulated Lipogenesis in Men," <i>Journal of Lipid Research</i> 39:1280-1286.			
SS	4.	Boersma, M.G. et al. (January 2001). "19F NMR Metabolomics for the Elucidation of Microbial Degradation Pathways of Flourophenols," <i>Ind. Microbial. Biotechnol.</i> 26(1/2):22-34.			
SS	5.	European Search Report mailed on August 9, 2006 for EP Patent Application No. 02782079.4, three pages.			
SS	6.	Griffin, J.L. et al. (June 1, 2001). "Metabolic Profiling of Genetic Disorders: A Multitissue ¹ H Nuclear Magnetic Resonance Spectroscopic and Pattern Recognition Study into Dystrophic Tissue," <i>Anal. Biochem.</i> 293(1):16-21.			
SS	7.	Jardine, A. et al. (December 1999). "Fluvastatin in Combination with Cyclosporin in Renal Transplant Recipients: A Review of Clinical and Safety Experience," <i>J. Clinical Pharmacy and Therapeutics</i> 24(6):397-408.			
SS	8.	Koletzko, B. et al. (1991). "Fatty Acid Composition of Mature Human Milk in Nigeria," <i>Zeitschrift Fur Ernaehrungswissenschaft</i> 30(4):289-297.			
SS	9.	Lithell, H. (1993). "Hypertension and Hyperlipidemia: A Review," <i>Am. J. of Hypertension</i> 6(11):303S-308S.			
SS	10.	Madsen, A. et al. (1992). "Influence of Dietary Fat of Carcass Fat Quality in Pigs: A Review," <i>Acta Agricultae Scandinavica</i> 42(4):220-225.			
SS	11.	Romo, G. A. et al. (November 2000). "Milk Composition and Apparent Digestibilities of Dietary Fatty Acids in Lactating Dairy Cows Abomasally Infused With Cis or Trans Fatty Acids," <i>Journal of Dairy Science</i> 83(11):2609-2619.			
SS	12.	Saunder, C.D. et al. (May 1979). "Lipid Metabolism in Diabetes Mellitus," <i>Am. J. Med.</i> 66(5):843-852.			
SS	13.	Siguel, E.N. et al. (July 1987). "Relative Activity of Unsaturated Fatty Acid Metabolic Pathways in Humans," <i>Metabolism</i> 36(7):664-669.			
SS	14.	Siguel, E.N. et al. (September 1986). "Monitoring the Optimal Infusion of Intravenous Lipids. Detection of Essential Fatty Acid Deficiency," <i>Arch. Pathol. Lab. Med.</i> 110(9):792-797.			
SS	15.	Tanaka, K. et al. (April 30, 1982). "Compilation of Gas Chromatographic Retention Indices of 163 Metabolically Important Organic Acids and Their Use in Detection of Patients with Organic			

Examiner Signature	/Sandra Saucier/	Date Considered	12/13/2006
--------------------	------------------	-----------------	------------


Substitute for form 1449/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/808,880
(Use as many sheets as necessary)				Filing Date	March 24, 2004
				First Named Inventor	Steven M. WATKINS
				Art Unit	1651
				Examiner Name	S. Saucier
Sheet	2	of	2	Attorney Docket Number	475512000400

		Acidurias," <i>J. Chromatogr.</i> 239:301-322.	
SS	16.	Tate, A.R. et al. (May-June 1996). "Lipid Metabolite Peaks in Pattern Recognition Analysis of Tumour in Vivo MR Spectra," <i>Anticancer Res.</i> 16(3B):1575-1579.	
SS	17.	Tweeddale, H. et al. (October 1998). "Effect of Slow Growth of Metabolism of <i>Escherichia coli</i> , as Revealed by Global Metabolite Pool ("Metabolome") Analysis," <i>J. Bacteriol.</i> 180(19):5109-5116.	
SS	18.	Vigneau-Callahan, K.E. et al. (March 2001). "Characterization of Diet-Dependent Metabolic Serotypes: Analytical and Biological Variability Issues in Rats," <i>J. Nutr.</i> 131(3):924S-932S.	
SS	19.	Waters, N.J. et al. (July 1, 2002). "NMR and Pattern Recognition Studies on Liver Extracts and Intact Livers for Rats Treated with Alpha-Naphthylisocyanate," <i>Biochem. Pharm.</i> 64(1):67-77.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Sandra Saucier/	Date Considered	12/13/2006
pa-1104663			



ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
Sheet	1	of	2	Application Number	10/808,880
				Filing Date	March 24, 2004
				First Named Inventor	Steven M. WATKINS
				Art Unit	1651
				Examiner Name	S. Saucier
				Attorney Docket Number	475512000400


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
SS	1.	US-2004/0024065-A1	02-05-2004	Watkins et al.	
SS	2.	US-2004/0143461-A1	07-22-2004	Watkins	
SS	3.	US-2006/0084129-A1	04-20-2006	Watkins	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		
					T ⁶

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
SS	4.	Füchtenbusch, M. et al. (2000). "Clinical Efficacy of New Thiazolidinediones and Glinides in the Treatment of Type 2 Diabetes Mellitus," <i>Exp. Clin. Endocrinol. Diabetes</i> 108:151-163.			
SS	5.	Holub, B.J. et al. (1987). "Nutritional Regulation of Cellular Phosphatidylinositol," Section 21 <i>In Methods in Enzymology</i> , Volume 141, Conn, P.M. et al. eds., Academic Press Inc.: Orlando, FL, pp. 234-244.			
SS	6.	Horton, J.D. et al. (May 2002). "SREBPs: Activators of the Complete Program of Cholesterol and Fatty Acid Synthesis in the Liver," <i>The Journal of Clinical Investigation</i> 109(9):1125-1131.			
SS	7.	Jump, D.B. et al. (1994). "Coordinate Regulation of Glycolytic and Lipogenic Gene Expression by Polyunsaturated Fatty Acids," <i>Journal of Lipid Research</i> 35:1076-1084.			
SS	8.	Kersten, S. et al. (June 1999). "Peroxisome Proliferator-Activated Receptor α Mediates the Adaptive response to Fasting," <i>The Journal of Clinical Investigation</i> 103(11):1489-1498.			
SS	9.	Kersten, S. (2001). "Mechanisms of Nutritional and Hormonal Regulation of Lipogenesis," <i>EMBO Reports</i> 2(41):282-286.			
SS	10.	Loftus, T.M. et al. (June 30, 2000). "Reduced Food Intake and Body Weight in Mice Treated With Fatty Acid Synthase Inhibitors," <i>Science</i> 288:2379-2381.			
SS	11.	Ruiz, J.I. et al. (1997). "Quantification in the Subnanomolar Range of Phospholipids and Neutral Lipids by Monodimensional Thin-Layer Chromatography and Image Analysis," <i>Journal of Lipid Research</i> 38:1482-1489.			
SS	12.	Semenkovich, C.F. (1997). "Regulation of Fatty Acid Synthase (FAS)," <i>Prog. Lipid Res.</i> 36(10):43-53.			
SS	13.	Siguel, E.N. et al. (October 1987). "Criteria for Essential Fatty Acid Deficiency in Plasma as Assessed by Capillary Column Gas-Liquid Chromatography," <i>Clin. Chem.</i> 33(10):1869-1873.			
SS	14.	Soukas, A. et al. (2000). "Leptin-Specific Patterns of Gene Expression in White Adipose Tissue," <i>Genes & Dev.</i> 14:963-980.			
SS	15.	Tretheway, R.N. (April 2001). "Gene Discovery via Metabolic Profiling," <i>Curr. Opin. Biotechnol.</i> 12(2):135-138.			
SS	16.	Watkins, S.M. et al. (2002). "Lipid Metabolome-Wide Effects of the PPAR γ Agonist Rosiglitazone," <i>J. Lipid Res.</i> 43:1809-1817.			

Examiner Signature	/Sandra Saucier/	Date Considered	12/13/2006
--------------------	------------------	-----------------	------------



ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/808,880
Sheet	2	of	2	Filing Date	March 24, 2004
				First Named Inventor	Steven M. WATKINS
				Art Unit	1651
				Examiner Name	S. Saucier
				Attorney Docket Number	475512000400

SS	17.	Yin, D. et al. (1998). "Somatotropin-Dependent Decrease in Fatty Acid Synthase mRNA Abundance in 3T3-F442A Adipocytes is the Result of a Decrease in Both Gene Transcription and mRNA Stability," <i>Biochem. J.</i> 331:815-820.	
----	-----	---	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Sandra Saucier/	Date Considered	12/13/2006
pa-1109449			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	6556-68013
		Application Number	_____
		Filing Date	Herewith
		First Named Inventor	Watkins
		Art Unit	
		Examiner Name	
U.S. PATENT DOCUMENTS			
Examiner's Initials*	Cite No. (optional)	Number	Date
FOREIGN PATENT DOCUMENTS			
Examiner's Initials*	Cite No. (optional)	Number	Date
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS	
SS		Awai, Koji, "Abnormal metabolism of fatty acids in diabetes," <i>Sogo Rinsho</i> , 17(3):549-564, 1968; Database Answer, Accession Number 69:25614	
SS		Gellhorn and Benjamin, "Lipid Biosynthesis in Adipose Tissue During Aging and in Diabetes," <i>Annals New York Academy of Sciences</i> , 131(1):344-356, 1976	
SS		Volpe and Marasa, "Regulation of Palmitic Acid Synthesis in Cultured Glial Cells: Effects of Glucocorticoid on Fatty Acid Synthetase, Acetyl-CoA Carboxylase, Fatty Acid and Sterol Synthesis," <i>J. Neurochemistry</i> , 27:841-845, 1976	
SS		Watkins, "Comprehensive Lipid Analysis: A Powerful Metonomic Tool for Predictive and Diagnostic Medicine," <i>IMAJ</i> , 2:722-724, September 2000	

EXAMINER SIGNATURE:	/Sandra Saucier/	DATE CONSIDERED:	12/13/2006
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.			